4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Cystic Fibrosis Clinical Trials to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cystic Fibrosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 117 ongoing clinical trials involving Cystic Fibrosis
Of the 117 trials,39 trials are in Phase II
Furthermore, 36 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Cystic Fibrosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cystic Fibrosis, a Respiratory condition. North America boasts of the highest number of ongoing clinical trials involving Cystic Fibrosis. Europe and Asia-Pacific are among some of the other prominent regions involved in Cystic Fibrosis -related drug trials.

Vertex Pharmaceuticals Inc: The leading ongoing Cystic Fibrosis -related clinical trials sponsor

Vertex Pharmaceuticals Inc, the United States of America-based pharmaceutical company, is the top sponsor for Cystic Fibrosis -related ongoing clinical trials.

University of Alabama at Birmingham, AbbVie Inc, Seattle Children's Hospital, National Jewish Health, and Shahid Beheshti University of Medical Sciences are a few other notable sponsors involving Cystic Fibrosis.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cystic Fibrosis

Elexacaftor/tezacaftor/ivacaftor, and ivacaftor (Kaftrio; Trikafta), Ivacaftor/Lumacaftor (Orkambi), and Ivacaftor (Kalydeco)are among the key marketed drugs involving Cystic Fibrosis.

Elexacaftor/tezacaftor/ivacaftor, and ivacaftor (Kaftrio; Trikafta) a Cystic Fibrosis Transmembrane Conductance Regulator Activator, is indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Trikafta is also indicated in the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data. The drug is marketed globally including in the US, the UK Australia, France, and Germany by Vertex Pharmaceuticals Inc. Elexacaftor/tezacaftor/ivacaftor, and ivacaftor was first approved in 2019 and formulated as film-coated tablets for oral route of administration.

Ivacaftor/Lumacaftor (Orkambi), a Cystic Fibrosis Transmembrane Conductance Regulator Activator. The drug is marketed globally including in the United States of America, Australia, France, and Germany by Vertex Pharmaceuticals Inc. Ivacaftor/Lumacaftor was first approved in 2015 and formulated as film-coated tablets and granules for oral route of administration.

Explore the latest trends and actionable insights on the Cystic Fibrosis Clinical Trials to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Cystic Fibrosis Clinical Trials to inform business strategy and pinpoint opportunities and risks. Visit Report Store